Prevalence, management and efficacy of treatment in portal vein obstruction after paediatric liver transplantation: protocol of the retrospective international multicentre PORTAL registry
Author:
Alfares Bader AORCID, van der Doef Hubert P J, Wildhaber Barbara E, Casswall Thomas, Nowak Greg, Delle Martin, Aldrian Denise, Berchtold Valeria, Vogel Georg FORCID, Kaliciński Piotr, Markiewicz-Kijewska Malgorzata, Kolesnik Adam, Bernabeu Jesús Q, Hally María Mercadal, Larrarte K Mauricio, Marra Paolo, Bravi Michela, Pinelli DomenicoORCID, Kasahara Mureo, Sakamoto Seisuke, Uchida Hajime, Mali Vidyadhar, Aw Marion, Franchi-Abella Stéphanie, Gonzales Emmanuel, Guérin Florent, Cervio Guillermo, Minetto Julia, Sierre Sergio, de Santibañes Martin, Ardiles Victoria, Uno Jimmy Walker, Evans Helen, Duncan David, McCall John, Hartleif Steffen, Sturm Ekkehard, Patel Jai, Mtegha Marumbo, Prasad Raj, Ferreira Cristina T, Nader Luiza S, Farina Marco, Jaramillo Catalina, Rodriguez-Davalos Manuel I, Feola Peter, Shah Amit A, Wood Phoebe M, Acord Michael R, Fischer Ryan T, Mullapudi Bhargava, Hendrickson Richard J, Khanna Rajeev, Pamecha Viniyendra, Mukund Amar, Sharif Khalid, Gupte Girish, McGuirk Simon, Porta Gilda, Spada Marco, Alterio Tommaso, Maggiore Giuseppe, Hardikar Winita, Beretta Marisa, Dierckx Rudi, de Kleine Ruben H J, Bokkers Reinoud P H
Abstract
IntroductionPortal vein obstruction (PVO) consists of anastomotic stenosis and thrombosis, which occurs due to a progression of the former. The aim of this large-scale international study is to assess the prevalence, current management practices and efficacy of treatment in patients with PVO.Methods and analysisThe Portal vein Obstruction Revascularisation Therapy After Liver transplantation registry will facilitate an international, retrospective, multicentre, observational study, with 25 centres around the world already actively involved. Paediatric patients (aged <18 years) with a diagnosed PVO between 1 January 2001 and 1 January 2021 after liver transplantation will be eligible for inclusion. The primary endpoints are the prevalence of PVO, primary and secondary patency after PVO intervention and current management practices. Secondary endpoints are patient and graft survival, severe complications of PVO and technical success of revascularisation techniques.Ethics and disseminationMedical Ethics Review Board of the University Medical Center Groningen has approved the study (METc 2021/072). The results of this study will be disseminated via peer-reviewed publications and scientific presentations at national and international conferences.Trial registration numberNetherlands Trial Register (NL9261).
|
|